FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894974201> ?p ?o ?g. }

• W2894974201 endingPage "1161" @default.
• W2894974201 startingPage "1152" @default.
• W2894974201 abstract "Cancer is an important public health problem, being one of the leading causes of death worldwide. Most antineoplastic agents cause severe toxic effects and some types of cancer do not respond or are resistant to the existing pharmacotherapy, necessitating the research and development of new therapeutic strategies. Cardenolides have shown significant antitumor activity due to their ability to inhibit the Na+K+ATPase enzyme, and the expression of this enzyme is increased in tumor cells. Glucoevatromonoside containing peracetylated glucose hydroxyl groups (GEVPG) is a cardenolide derivative that has low solubility in aqueous media, which constitutes a barrier to its potential biological applications. In this context, the use of liposomes represents a promising strategy to deliver GEVPG, thus allowing its intravenous administration. In this study, long-circulating and fusogenic liposomes containing GEVPG (SpHL-GEVPG) were developed, and their chemical and physicochemical properties were evaluated. SpHL-GEVPG presented adequate properties, including a mean diameter of 182.2 ± 2.7 nm, a polydispersity index equal to 0.36 ± 0.03, a zeta potential of –2.37 ± 0.31 mV, and a GEVPG entrapment of 0.38 ± 0.04 mg/mL. Moreover, this formulation showed a good stability after having been stored for 30 days at 4 °C. The cytotoxic studies against breast (MDA-MB-231, MCF-7, and SKBR-3) and lung (A549) cancer cell lines demonstrated that SpHL-GEVPG treatment significantly reduced the cell viability. In addition, the SpHL-GEVPG formulation presented a good selectivity toward these cancer cells. The evaluation of the therapeutic efficacy of the treatment with SpHL-GEVPG showed a potent anticancer effect in an A549 human lung cancer xenograft model. SpHL-GEVPG administered at doses of 1.0 and 2.0 mg/kg (i.v.) induced antitumor effect comparable to paclitaxel given at dose of 10 mg/kg (i.v.) to mice. Therefore, the results of the present work indicate the potential applicability of SpHL-GEVPG as a new anticancer formulation." @default.
• W2894974201 created "2018-10-12" @default.
• W2894974201 creator A5012083729 @default.
• W2894974201 creator A5027149125 @default.
• W2894974201 creator A5031512843 @default.
• W2894974201 creator A5032214339 @default.
• W2894974201 creator A5042148885 @default.
• W2894974201 creator A5042832806 @default.
• W2894974201 creator A5044620914 @default.
• W2894974201 creator A5049236802 @default.
• W2894974201 creator A5063183671 @default.
• W2894974201 creator A5083740080 @default.
• W2894974201 creator A5086014583 @default.
• W2894974201 date "2018-12-01" @default.
• W2894974201 modified "2023-10-15" @default.
• W2894974201 title "Long-circulating and fusogenic liposomes loaded with a glucoevatromonoside derivative induce potent antitumor response" @default.
• W2894974201 cites W1845439236 @default.
• W2894974201 cites W1982572987 @default.
• W2894974201 cites W2003110090 @default.
• W2894974201 cites W2008722476 @default.
• W2894974201 cites W2011770185 @default.
• W2894974201 cites W2013394982 @default.
• W2894974201 cites W2020678484 @default.
• W2894974201 cites W2022137114 @default.
• W2894974201 cites W2027542963 @default.
• W2894974201 cites W2029772834 @default.
• W2894974201 cites W2044647958 @default.
• W2894974201 cites W2051925512 @default.
• W2894974201 cites W2052874737 @default.
• W2894974201 cites W2067615308 @default.
• W2894974201 cites W2068971025 @default.
• W2894974201 cites W2070198605 @default.
• W2894974201 cites W2070358111 @default.
• W2894974201 cites W2085753859 @default.
• W2894974201 cites W2121964995 @default.
• W2894974201 cites W2132741431 @default.
• W2894974201 cites W2132834292 @default.
• W2894974201 cites W2147186490 @default.
• W2894974201 cites W2163882233 @default.
• W2894974201 cites W2166458266 @default.
• W2894974201 cites W2170254419 @default.
• W2894974201 cites W2317485478 @default.
• W2894974201 cites W2344275211 @default.
• W2894974201 cites W2359219670 @default.
• W2894974201 cites W2412064534 @default.
• W2894974201 cites W2496851647 @default.
• W2894974201 cites W2587009424 @default.
• W2894974201 cites W2612478200 @default.
• W2894974201 cites W2767488254 @default.
• W2894974201 cites W2767707410 @default.
• W2894974201 cites W2794254026 @default.
• W2894974201 cites W2800579137 @default.
• W2894974201 cites W4247115498 @default.
• W2894974201 doi "https://doi.org/10.1016/j.biopha.2018.09.109" @default.
• W2894974201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30372816" @default.
• W2894974201 hasPublicationYear "2018" @default.
• W2894974201 type Work @default.
• W2894974201 sameAs 2894974201 @default.
• W2894974201 citedByCount "10" @default.
• W2894974201 countsByYear W28949742012020 @default.
• W2894974201 countsByYear W28949742012021 @default.
• W2894974201 countsByYear W28949742012022 @default.
• W2894974201 crossrefType "journal-article" @default.
• W2894974201 hasAuthorship W2894974201A5012083729 @default.
• W2894974201 hasAuthorship W2894974201A5027149125 @default.
• W2894974201 hasAuthorship W2894974201A5031512843 @default.
• W2894974201 hasAuthorship W2894974201A5032214339 @default.
• W2894974201 hasAuthorship W2894974201A5042148885 @default.
• W2894974201 hasAuthorship W2894974201A5042832806 @default.
• W2894974201 hasAuthorship W2894974201A5044620914 @default.
• W2894974201 hasAuthorship W2894974201A5049236802 @default.
• W2894974201 hasAuthorship W2894974201A5063183671 @default.
• W2894974201 hasAuthorship W2894974201A5083740080 @default.
• W2894974201 hasAuthorship W2894974201A5086014583 @default.
• W2894974201 hasBestOaLocation W28949742011 @default.
• W2894974201 hasConcept C109316439 @default.
• W2894974201 hasConcept C121608353 @default.
• W2894974201 hasConcept C126322002 @default.
• W2894974201 hasConcept C150903083 @default.
• W2894974201 hasConcept C151730666 @default.
• W2894974201 hasConcept C181199279 @default.
• W2894974201 hasConcept C185154212 @default.
• W2894974201 hasConcept C185592680 @default.
• W2894974201 hasConcept C190283241 @default.
• W2894974201 hasConcept C202751555 @default.
• W2894974201 hasConcept C207001950 @default.
• W2894974201 hasConcept C2779343474 @default.
• W2894974201 hasConcept C53227056 @default.
• W2894974201 hasConcept C55493867 @default.
• W2894974201 hasConcept C71924100 @default.
• W2894974201 hasConcept C86803240 @default.
• W2894974201 hasConcept C96232424 @default.
• W2894974201 hasConcept C98274493 @default.
• W2894974201 hasConceptScore W2894974201C109316439 @default.
• W2894974201 hasConceptScore W2894974201C121608353 @default.
• W2894974201 hasConceptScore W2894974201C126322002 @default.
• W2894974201 hasConceptScore W2894974201C150903083 @default.
• W2894974201 hasConceptScore W2894974201C151730666 @default.

• next